Daniel Kohlstaedt, managing director and founder of PurpleLeaf Strategy, explores the ways brand leaders can leverage specific brand planning tools as an alternative to full suite platforms
Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.